Allergy

>

Latest News

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization
Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

February 24th 2023

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis
Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis

October 24th 2022

Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data
Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data

July 13th 2022

FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis
FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis

May 23rd 2022

Tezepelumab for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities
Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities

February 28th 2022

More News

© 2023 MJH Life Sciences

All rights reserved.